ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Animal-Health Deals In The Offing

by Ann M. Thayer
September 28, 2009 | APPEARED IN VOLUME 87, ISSUE 39

[+]Enlarge
Credit: Merial
Animal health is big business.
8739bcon_12.jpg
Credit: Merial
Animal health is big business.

To satisfy regulators before they merge, Pfizer and Wyeth have agreed to sell certain Wyeth animal-health assets to Boehringer Ingelheim. The German company will acquire vaccines and some drug products, primarily in the U.S. and Canada, along with research and manufacturing facilities located in Fort Dodge, Iowa. Boehringer may also gain certain other assets in Australia, South Africa, and the European Union, pending regulatory approvals. The companies did not disclose any financial details. Separately, Sanofi-Aventis has completed its $4 billion purchase of Merck & Co.’s 50% interest in their animal-health joint venture, Merial.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment